Despite a regulatory crackdown, unapproved peptides are still being openly sold across dozens of Australian websites, and more people are landing in emergency departments with serious side effects. The Therapeutic Goods Administration has seized nearly a million illicit pharmaceutical units and issued heavy fines, but experts say the online market is only growing. Doctors warn that these unverified products carry real risks — regardless of how they're taken.
Despite a major crackdown by Australia's Therapeutic Goods Administration (TGA), unapproved peptides are still being openly marketed and sold across dozens of websites — and the health consequences are mounting. Medscape News Australia identified 30 online vendors and 13 clinics promoting unapproved peptides like melanotan II, BPC-157, and retatrutide, many of which are prescription-only or have never been tested in humans. Vendors frequently use "research purposes only" disclaimers to skirt regulations, a tactic experts say is legally meaningless.
The TGA has taken action — seizing nearly a million illicit pharmaceutical units in a global operation, shutting down 5,700 online sellers, and issuing over $100,000 in fines to one NSW supplier. Still, a Queensland harm-reduction helpline now fields more than 10 calls per week about peptides, a noticeable jump from six months ago. Experts warn that product quality is unverifiable: one retatrutide vial was found to contain nearly double its labeled concentration, and a 2018 study found illicit peptides containing arsenic and lead.
By the Numbers:
Why it matters: Unregulated peptides represent a fast-growing public health risk. With no quality controls, consumers have no way to know what's actually in the vial — and the consequences range from liver damage to life-threatening allergic reactions.
